CD274 and cancer: Monoclonal antibody blockade of the PD-1/PD-L1 pathway demonstrated clinical activity in several types of cancers, such as non-small cell lung cancer [5, 6], melanoma [7], renal cell carcinoma [8, 9], and hematological malignancies including relapsed/refractory classic Hodgkin lymphoma (HL) [10].